Patient Name	Mrs. KANIKA KALRA	Lab No	4027897	
UHID	40011906	Sample Date	20/03/2024 9:10AM	
Age/Gender	35 Yrs/Female	Report Date	20/03/2024 12:35PM	
Prescribed By	Dr. EHS CONSULTANT	Bed No / Ward	OPD	
Referred By	Dr. EHS CONSULTANT	<b>Report Status</b>	Final	
Company	Mediwheel - Arcofemi Health Care Ltd.			
	C	YTOLOGY		
CYTOLOGY*				
Type of Specimen		Pap smear (Conventional)		
No. of smears examined		Тwo		
		Unsatisfactory for evaluation		
Adequacy		Adequate		
Endocervical cells		Not seen.		
nflammation		Marked acute inflammation		
Organisms		Not seen.		
Epithelial cell abnormality	,	Not seen		
Others				
		Blood		
mpression		Unsatisfactory for evaluation	due to marked inflammation	
Advice		To repeat once after control	of inflammation	
Note: Test marked as * a Bethesda2014	are not accreditedby NABL			

-----\*\* End Of Report \*\*-----

Abrinary

Dr. ABHINAY VERMA MBBS|MD|INCHARGE PATHOLOGY

Patient Name UHID	Mrs. KANIKA KALRA 40011906		Lab Coll	No ection Date	4027897 20/03/2024 9:10	DAM
Age/Gender	35 Yrs/Female			eiving Date	20/03/2024 9:1	7AM
IP/OP Location	O-OPD		Rep	ort Date	20/03/2024 2:04	4PM
Referred By	Dr. EHS CONSULTANT		Rep	ort Status	Final	
Mobile No.	8879878242					
			BIOCHEMISTRY			
Test Name		Result	Unit	Biolog	ical Ref. Range	
	STINC)					Complex El Disema
BLOOD GLUCOSE (FA						Sample: Fi. Plasma
BLOOD GLUCOSE (FA		89	mg/dl	71 - 109		Sample: Fl. Plasma
BLOOD GLUCOSE (FA Method: Hexokinase Interpretation:-Di	STING)		-		arbohydrate metabol	·
BLOOD GLUCOSE (FA Method: Hexokinase	STING) assay. agnosis and monitoring o		-		arbohydrate metabol	·

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH				Sample: Serum
ТЗ	1.130	ng/mL	0.970 - 1.690	
Τ4	6.36	ug/dl	5.53 - 11.00	
TSH	2.41	μlU/mL	0.40 - 4.05	

**RESULT ENTERED BY : SUNIL EHS** 



#### Dr. ABHINAY VERMA

Patient Name	Mrs. KANIKA KALRA
UHID	40011906
Age/Gender	35 Yrs/Female
IP/OP Location	O-OPD
Referred By	Dr. EHS CONSULTANT
Mobile No.	8879878242

Lab No Collection Date Receiving Date Report Date Report Status 4027897 20/03/2024 9:10AM 20/03/2024 9:17AM 20/03/2024 2:04PM Final

### BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in the diagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in theconcentrations of the free thyroid hormones bring about much greater oppositechanges in the TSH levels.

#### LFT (LIVER FUNCTION TEST)

BILIRUBIN TOTAL	0.43	mg/dl	0.00 - 1.20
BILIRUBIN INDIRECT	0.25	mg/dl	0.20 - 1.00
BILIRUBIN DIRECT	0.18	mg/dl	0.00 - 0.30
SGOT	35.0 H	U/L	0.0 - 32.0
SGPT	48.0 H	U/L	0.0 - 33.0
TOTAL PROTEIN	7.3	g/dl	6.6 - 8.7
ALBUMIN	4.6	g/dl	3.5 - 5.2
GLOBULIN	2.7		1.8 - 3.6
ALKALINE PHOSPHATASE	93	U/L	35 - 104
A/G RATIO	1.7	Ratio	1.5 - 2.5
GGTP	14.0	U/L	0.0 - 40.0

**RESULT ENTERED BY : SUNIL EHS** 



#### Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Sample: Serum

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

#### BIOCHEMISTRY

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

**SGPT - ALT** :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder. ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status. ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE :- Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	199		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	51.1		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	125.9		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	24	mg/dl	10 - 50
TRIGLYCERIDES	122		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	4	%	

#### **RESULT ENTERED BY : SUNIL EHS**

AlbinaryVan

#### Dr. ABHINAY VERMA

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

#### BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.

CHOLESTEROL VLDL :- Method: VLDL Calculative

Interpretation:-High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

UREA 28.80 mg/dl 16.60 - 48.50 BUN 13 mg/dl 6 - 20 CREATININE 0.71 mg/dl 0.50 - 0.90 SODIUM 136 mmol/L 136 - 145 POTASSIUM 4.20 mmol/L 3.50 - 5.50 CHLORIDE 98 - 107 104.1 mmol/L URIC ACID 5.0 mg/dl 2.4 - 5.7 CALCIUM 9.85 mg/dl 8.60 - 10.00

**RESULT ENTERED BY : SUNIL EHS** 



Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Sample: Serum

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

#### BIOCHEMISTRY

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease. URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume. SODIUM: - Method: ISE electrode. Interpretation: -Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the

kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption. POTASSIUM :- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure. CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usuallyassociated with hypercalcemia. Increased serum calcium levels may also beobserved in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

HBA1C

4.8

%

< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6 4% Indicate Diabetes

Known Diabetic Patients

< 7 % Excellent Control

7 - 8 % Good Control > 8 % Poor Control

Method : - Turbidimetric inhibition immunoassay (TINIA)

Interpretation: -Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

**RESULT ENTERED BY : SUNIL EHS** 

Alerinary Van

MBBS | MD | INCHARGE PATHOLOGY

Sample: WHOLE BLOOD EDTA

Patient Name UHID	Mrs. KANIKA KALRA 40011906	Lab No Collection Date	4027897 20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

### **BLOOD BANK INVESTIGATION**

Test Name	Result	Unit	Biological Ref. Range

**BLOOD GROUPING** 

"O" Rh Positive

Note :

Both forward and reverse grouping performed.
Test conducted on EDTA whole blood.

**RESULT ENTERED BY : SUNIL EHS** 

AllineyVana

Dr. ABHINAY VERMA

Patient Name UHID	Mrs. KANIKA KALRA 40011906	Lab No Collection Date	4027897 20/03/2024 9:10AM	
Age/Gender	35 Yrs/Female	Receiving Date Report Date	20/03/2024 9:17AM	
IP/OP Location Referred By	O-OPD Dr. EHS CONSULTANT	Report Status	20/03/2024 2:04PM Final	
Mobile No.	8879878242			

### **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				p
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	HAZY		CLEAR	
CHEMICAL EXAMINATION				
РН	7.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.005		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	TRACE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	4-6	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	2-3	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

**RESULT ENTERED BY : SUNIL EHS** 

AbunayVana

Dr. ABHINAY VERMA

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

### **CLINICAL PATHOLOGY**

BACTERIA	NIL	NIL
OHTERS	NIL	NIL

Methodology:-

Methodology:-Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY : SUNIL EHS** 

Alerinary Van

**Dr. ABHINAY VERMA** 

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

### HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Ra	inge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	11.7 L	g/dl	12.0 - 15.0	
PACKED CELL VOLUME(PCV)	38.2	%	36.0 - 46.0	
MCV	63.0 L	fl	82 - 92	
MCH	19.3 L	pg	27 - 32	
MCHC	30.6 L	g/dl	32 - 36	
RBC COUNT	6.06 H	millions/cu.mm	3.80 - 4.80	
TLC (TOTAL WBC COUNT)	7.80	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	58.3	%	40 - 80	
LYMPHOCYTE	35.0	%	20 - 40	
EOSINOPHILS	1.2	%	1 - 6	
BASOPHIL	0.6 L	%	1 - 2	
MONOCYTES	4.9	%	2 - 10	
PLATELET COUNT	3.26	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia. MCV :- Method:- Calculation bysysmex. MCH :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex. RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.

TLC (TOTAL WEC COUNT) :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.

**NEUTROPHILS** :- Method: Optical detectorblock based on Flowcytometry

LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry

EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry

BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)

10

mm/1st hr 0 - 15

**RESULT ENTERED BY : SUNIL EHS** 

AlerinaryVan

Dr. ABHINAY VERMA

Patient Name	Mrs. KANIKA KALRA	Lab No	4027897
UHID	40011906	Collection Date	20/03/2024 9:10AM
Age/Gender	35 Yrs/Female	Receiving Date	20/03/2024 9:17AM
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8879878242		

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

**RESULT ENTERED BY : SUNIL EHS** 

Patient Name UHID	Mrs. KANIKA KALRA 40011906	Lab No Collection Date	4027897 20/03/2024 9:10AM	
Age/Gender	35 Yrs/Female	<b>Receiving Date</b>	20/03/2024 9:17AM	
IP/OP Location	O-OPD	Report Date	20/03/2024 2:04PM	
Referred By	Dr. EHS CONSULTANT	Report Status	Final	
Mobile No.	8879878242			
Х Кау				

**Test Name** 

Result

Unit

**Biological Ref. Range** 

### X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically& with other related investigations.

\*\*End Of Report\*\*

**RESULT ENTERED BY : SUNIL EHS** 



**APOORVA JETWANI** 

Select

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40011906 (8473)	<b>RISNo./Status :</b>	4027897/
Patient Name :	Mrs. KANIKA KALRA	Age/Gender :	35 Y/F
<b>Referred By :</b>	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	20/03/2024 8:46AM/ OPSCR23- 24/16148	Scan Date :	
<b>Report Date :</b>	20/03/2024 12:25PM	<b>Company Name:</b>	Final

### **REFERRAL REASON: HEALTH CHECKUP**

### 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

#### **M MODE DIMENSIONS: -**

			No	rmal				Normal
IVSD	10.9	6-12mm		LVIDS	28.1	20-40mm		
LVIDD	43.5		32-	57mm		LVPWS	17.2	mm
LVPWD	10.9		6-1	2mm		AO	28.1	19-37mm
IVSS	17.2		J	nm		LA	32.6	19-40mm
LVEF	62-64		>	55%		RA	-	mm
	DOPPLER	R MEA	SUREN	IENTS &	& CALC	ULATIONS	:	
STRUCTURE	MORPHOLOGY		VELOC	CITY (m	/s)	GRADIENT		REGURGITATION
				( <b>mmHg</b> )				
MITRAL	NORMAL	Ε	1.08	e'	-	-		NIL
VALVE		Α	0.70	E/e'	-			
TRICUSPID	NORMAL	E 0.58		-		NIL		
VALVE		A 0.47						
		A 0.47						
AORTIC	NORMAL	1.11		-		NIL		
VALVE								
PULMONARY	NORMAL	0.84				NIL		
VALVE						-		

### **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

#### **IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS**

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA MBBS, PGDCC, FIAE CONSULTANT & INCHARGE EMERGENCY, PREVENTIVE CARDIOLOGY AND WELLNESS CENTRE

# **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40011906 (8473)	<b>RISNo./Status :</b>	4027897/
Patient Name :	Mrs. KANIKA KALRA	Age/Gender :	35 Y/F
<b>Referred By :</b>	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	20/03/2024 8:46AM/ OPSCR23- 24/16148	Scan Date :	
Report Date :	20/03/2024 10:33AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

### ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver:	Normal in size & echotexture. No obvious significant focal parenchymal mass lesion			
	noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.			
Gall Bladder:	Lumen is clear. Wall thickness is normal. CBD is normal.			
Pancreas:	Normal in size & echotexture.			
Spleen:	Normal in size & echotexture. No focal lesion seen.			
<b>Right Kidney:</b>	Normal in shape, size & location. Echotexture is normal. Corticomedullary			
	differentiation is maintained. No evidence of significant hydronephrosis or obstructive			
	calculus noted.			
Left Kidney:	Normal in shape, size & location. Echotexture is normal. Corticomedullary			
	differentiation is maintained. No evidence of significant hydronephrosis or obstructive			
	calculus noted.			
Urinary Bladder:	Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall			
	thickness is normal.			
Uterus:	Normal in size, shape & anteverted in position. No mass lesion is seen. Cervix is			
	normal. IUCD seen in situ.			
Both ovaries:	Bilateral ovaries are normal in size, shape & volume.			
Others:	No significant free fluid is seen in pelvic peritoneal cavity.			
IMPRESSION: USG findings are suggestive of				
No signif	icant sonographic abnormality noted.			

Correlate clinically & with other related investigations.

tions

DR. APOORVA JETWANI Incharge & Senior Consultant Radiology MBBS, DMRD, DNB Reg. No. 26466, 16307